Amrize Ltd (AMRZ) Stock Analysis
Is AMRZ a good investment?
Amrize Ltd (AMRZ) has a Plutrex AI rating of 69.0/100 as of October 01, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: PEG of 1.14x is 42.7% below the Construction Materials industry average of 1.985x, while 5-year forward EPS growth of 15.1% marginally exceeds the 14.79% sector average — investors are paying the steepest growth discount in the peer group for above-average long-term earnings momentum; analyst consensus target of $49.70 implies 32.9% upside. Main concern: Analyst target has been serially cut from $61.98 → $49.70 (a cumulative -20.1% reduction across four revisions); current stabilization at $49.70 (+$0.00 this period) is not a reversal — risk of further consensus deterioration remains elevated, amplified by Section 338 tariffs on Canadian goods adding incremental pressure to the already 810 bps below-peer gross margin of 25.02%.
Investment Summary
AMRZ is a Construction Materials company trading at $37.39 with a 32.9% discount to the $49.70 analyst consensus target. The stock offers a compelling growth-adjusted valuation: PEG of 1.14x sits 42.7% below the industry average of 1.985x, while its 5-year forward EPS growth of 15.1% marginally exceeds the sector average of 14.79%. At a P/E of 17.19x — 16% below the peer average of 20.47x — the market is pricing AMRZ as a low-growth peer despite credible long-term earnings acceleration. Operating margin of 20.49% leads peers by ~350 bps despite a gross margin deficit (25.02% vs. 32.98% industry). FCF of $1.321B substantially exceeds net income, reflecting high earnings quality. Balance sheet is fortress-grade: D/E of 0.39x versus peer average 0.65x, with $729M cash. Key insider buying — CEO Jan Philipp Jenisch purchased 30,000 shares for $1.3M — provides confidence from the top. Primary risks remain: analyst target has been serially cut (from $61.98 to $49.70, a 20%+ cumulative reduction), Section 338 tariffs on Canadian goods press the already-thin 25% gross margin, and simultaneous leadership transitions (CFO, Building Envelope President, VP-IR) add execution uncertainty. No material metrics moved since the prior report 7 days ago; anchoring applies and all ratings are held stable.
Key Strengths
- PEG of 1.14x is 42.7% below the Construction Materials industry average of 1.985x, while 5-year forward EPS growth of 15.1% marginally exceeds the 14.79% sector average — investors are paying the steepest growth discount in the peer group for above-average long-term earnings momentum; analyst consensus target of $49.70 implies 32.9% upside
- Fortress balance sheet: FCF of $1.321B materially exceeds net income, $729M cash, D/E of 0.39x (40% below peer average of 0.65x), and operating margin of 20.49% leading peers by ~350 bps — provides cycle resilience and financial flexibility in a capital-intensive sector with tariff headwinds
- Meaningful senior insider buying with conviction: CEO Jan Philipp Jenisch purchased 30,000 shares for $1.3M and Chief Strategy Officer purchased 2,510 shares for ~$118K — at-market purchases by executives with full pipeline visibility, particularly significant near a 28%+ drawdown from IPO-era prices
Key Concerns
- Analyst target has been serially cut from $61.98 → $49.70 (a cumulative -20.1% reduction across four revisions); current stabilization at $49.70 (+$0.00 this period) is not a reversal — risk of further consensus deterioration remains elevated, amplified by Section 338 tariffs on Canadian goods adding incremental pressure to the already 810 bps below-peer gross margin of 25.02%
- Simultaneous leadership transition risk remains: new CFO Sam Poletti, new Building Envelope President Mario Gross, and new VP of Investor Relations Dillon Cumming all appointed near-simultaneously post-June 2025 IPO — execution uncertainty during a critical first year as a public company when the company must deliver 15.1% EPS growth to justify even its current discounted valuation
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Profitability: Gross margin 25.02% is materially below the 32.98% industry average (-24.1%), limiting pricing power. Operating margin 20.49% beats the 16.95% peer average (+20.8%), demonstrating exceptional SG&A discipline. Net margin 9.89% modestly exceeds peers at 9.11% (+8.6%). ROE of 9.53% trails the 11.57% peer average (-17.6%), partly structural given the conservative D/E of 0.39x vs. 0.65x peers. Valuation: P/E 17.19x vs. 20.47x peers; PEG 1.14x vs. 1.985x peers — AMRZ is the cheapest stock on growth-adjusted basis in its 25-peer Construction Materials cohort. Growth: Revenue growth 8.6% trails the 10.7% peer average; historical earnings growth 14.7% close to forward 5-year EPS projection of 15.1%, lending credibility. Near-term forward EPS (13.85%) lags peers (16.04%), but the 5-year outlook flips AMRZ to a slight leader. Financial Health: FCF $1.321B >> net income, $729M cash, D/E 0.39x — sector-leading balance sheet. The central tension: impressive operational discipline and valuation discount vs. persistent gross margin weakness, top-line growth deficit, and the gap between 8.6% revenue growth and 15.1% EPS growth requiring margin expansion and/or buybacks to close.
News Sentiment
Amrize is making big moves to shore up investor confidence — and insiders are literally putting their money where their mouth is. CEO Jan Philipp Jenisch recently dropped $1.3 million of his own money to buy 30,000 shares of the company, a bold bet that the stock's recent weakness is overdone. The Chief Strategy Officer also joined in, snapping up 2,510 shares for nearly $118,000. These aren't symbolic gestures — they're real money from executives who know exactly what's in the pipeline. On the leadership front, Amrize named Dillon Cumming as its new Vice President of Investor Relations, a hire that signals the company is serious about its Wall Street communication game, especially important for a company that only went public in June 2025. The company also brought in Mario Gross as President of Building Envelope, adding a fresh voice to a key business unit. Institutional investors are taking notice: Oakmark Global Strategy added Amrize to its Q2 2026 portfolio, lending the stock credibility with the smart-money crowd. Analysts point to healthy end markets and margin recovery as reasons to be optimistic about the upside case. One cloud on the horizon: the company is among stocks flagged as facing new pressure from Section 338 tariffs on Canadian goods, which could squeeze already-tight profit margins. But with a cost savings program called ASPIRE in motion, management is clearly fighting back. The big picture: Amrize looks like a company in transition — navigating new leadership, tariff headwinds, and a post-IPO credibility test — with insiders betting the story will have a happy ending.
Risk Assessment
PRIMARY RISK: Analyst revision cycle has not reversed — four consecutive target cuts from $61.98 to $49.70 (-20.1%) could continue if tariff headwinds or leadership transitions produce earnings misses; each cut would compress the upside case. SECONDARY RISK: Section 338 tariffs on Canadian goods directly pressure gross margins (already 810 bps below peers at 25.02%); a 100-200 bps gross margin compression would reduce FCF and potentially trigger another downward revision cycle. TERTIARY RISK: Revenue growth of 8.6% trails peers by 19.6%; the 15.1% EPS growth target depends heavily on margin expansion and buybacks — if revenue stalls further, EPS growth projection credibility erodes. MITIGATION: Stop at $34.00 (9.3% below entry midpoint $37.50) limits drawdown to 9.3% of entry, while 32.9% upside to $49.70 target yields a 3.5x risk/reward ratio. CEO's $1.3M personal purchase at ~$43/share provides psychological support. Conservative 2.5% position size reflects Low conviction.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is AMRZ a halal stock?
No, Amrize Ltd (AMRZ) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for AMRZ?
Amrize Ltd (AMRZ) has a Plutrex AI rating of 69.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is AMRZ a good investment?
According to Plutrex AI, AMRZ has a Buy rating (69.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in AMRZ?
US stocks like AMRZ can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in AMRZ?
Plutrex AI identifies the main risks for AMRZ by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.